MAPKAPK5-AS1 and myositis disease: Recent studies have identified several myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs), each of which is associated with distinct clinical phenotypes and outcomes [1,2,6,7,8,9].